EFhd1蛋白在非小细胞肺癌组织中的表达及临床意义  

Expression and clinical significance of EFhd1 in patients with non-small cell lung cancer

作　　者：许立芹[1] 吕梦源 冯健[1] Liqin;Lyu Mengyuan;Feng Jian(Department of Respiratory Medicine,Affiliated Hospital of Nantong University, Nantong 226001,China)

机构地区：[1]南通大学附属医院呼吸与危重症医学科

出　　处：《中华肺部疾病杂志（电子版）》2019年第5期573-578,共6页Chinese Journal of Lung Diseases(Electronic Edition)

基　　金：南通市新型诊疗技术攻关项目(MS12018038);南通市应用基础研究关键技术重点研发专项(MS12017005-1);南通市卫健委青年基金(WQ2016077)

摘　　要：目的探讨EFhd1蛋白在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法收集南通大学附属医院心胸外科2004年1月至2011年4月收治的178例NSCLC手术患者的病例及其相应的临床病理和随访资料,并制备组织芯片;采用免疫组化方法检测EFhd1蛋白的表达,统计分析EFhd1蛋白与NSCLC患者临床病理参数、预后之间的相关性。结果 EFhd1在NSCLC组织(43.3%,77/178)中的表达明显高于癌旁组织(2.0%,1/51),差异有统计学意义(P<0.05)。统计分析显示:EFhd1的表达与T分期有关(P<0.05);Cox单因素分析显示,患者的TNM分期、T分期、N分期与NSCLC的预后密切相关(P<0.01);多因素分析显示EFhd1的高表达以及TNM分期为NSCLC的独立预后因素(P<0.05)。生存曲线提示EFhd1高表达的患者较EFhd1低表达患者生存期短,预后差,TNM分期越晚则生存时间越短。结论 EFhd1在NSCLC癌组织中的表达较癌旁组织中明显增高;TNM分期和EFhd1蛋白表达程度是影响患者预后的独立危险因素;EFhd1基因的高表达与患者的不良预后密切相关;EFhd1可作为NSCLC诊断及判断预后的潜在分子标记物,为后续研究其作为NSCLC靶向治疗的基因靶点的可能性提供了理论基础。Objective To investigate the expression of EFhd1 and its potential value as a prognostic indicator of survival in the patients with primary non-small cell lung cancer( NSCLC). Methods A total of178 NSCLC tissue specimens and 51 paracancerous tissue specimens were collected from 178 NSCLC surgical patients from January 2004 to April 2011 in the Cardiothoracic Surgery Department of the Affiliated Hospital of Nantong University. The clinical data and follow-up data were collected,too. Immunohistochemical analysis with tissue microarray was used to characterize the expression of EFhd1 in the NSCLC tissues. The relationship between the EFhd1 expression and the clinical characteristics and prognosis was determined by statistical analysis. Results The level of EFhd1 expression was higher in the NSCLC tissues than in the paracancerous tissues( P< 0. 05). The EFhd1 expression in the NSCLC tissues was related to the T staging( P < 0. 05).Univariate analysis revealed that TNM stage,T stage and N stage were associated with the prognosis of NSCLC( P< 0. 01). Kaplan Meier survival and Cox regression analyses revealed that the higher level of EFhd1 expression( P = 0.037) and later stage grouping by TNM( P = 0.001) were independent factors predicting poor prognosis for the patients with NSCLC. Conclusion The level of EFhd1 expression in the NSCLC tissues is significantly higher than that in the adjacent tissues. Our finding provides the first evidence that the higher level of EFhd1 expression is associated with the poor prognosis of the patients with NSCLC.

关 键 词：EFhd1 非小细胞肺癌 免疫组化 临床病理参数 预后 

分 类 号：R734.2[医药卫生—肿瘤]